One to three weeks
Source-claimed sleep timeline; not trial measured.
Protocol / Research Dosing Guide
CJC-1295 without DAC + Ipamorelin Blend Guide
A transparent blend reference separating clinic-blog schedules from evidence for the unstudied fixed combination.
Last reviewed September 15, 202619 minute readResearch information only
Level 1 — Blend not directly studiedClinic/community protocol onlyNot FDA approved
CJC-1295 without DAC + Ipamorelin Quick Start
This vendor-defined blend combines short-acting Mod GRF(1-29) with Ipamorelin. No controlled human or animal study of the fixed 1:1 mixture was identified, so component findings cannot establish blend efficacy or safety.
Why researchers care
Combined growth-hormone secretagogue research
Class
Fixed GHRH-analogue and ghrelin-receptor-agonist blend
Route reported
Subcutaneous use is source reported
Cycle length
12–16 weeks reported; not validated
Regulatory status
Research-use listing; not FDA approved
Loading supplier information
CJC-1295 without DAC + Ipamorelin Dosing Protocol and Schedule
The supplied clinic blog reports 100–200 mcg of each component one to three times daily. Its numeric schedules and outcome timelines are uncited clinical-marketing claims, not trial parameters.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| First 2–4 weeks | 100 mcg + 100 mcg once daily | Clinic-blog conservative pattern |
| Standard | 100–200 mcg of each | Two times daily; clinic-blog claim |
| Advanced | 200–300 mcg of each | Three times daily; clinic-blog claim |
No study validates the blend amount, 1:1 ratio, timing, frequency, cycle, rest period, same-syringe compatibility, or escalation.
CJC-1295 without DAC + Ipamorelin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
CJC-1295 without DAC + Ipamorelin Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.04 mL
U-100 units
4
Mathematical draws
50
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take CJC-1295 without DAC + Ipamorelin: Morning or Night?
Fasted timing
The clinic blog recommends fasted windows; no blend trial validates this.
Pre-sleep timing
Source reported, not clinically established.
Once to three times daily
Clinic-blog pattern only.
Missed amount
No validated procedure exists.
CJC-1295 without DAC + Ipamorelin Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Subcutaneous | Clinic/community reported | No blend trial |
| Same syringe | Claimed compatible by supplied blog | No cited compatibility study |
| Oral or nasal | Not established | No exposure data |
| Separate components | Different evidence records | Not proof for fixed blend |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
CJC-1295 without DAC + Ipamorelin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Blend half-life | Not established | No combination PK study |
| CJC without DAC | About 30 minutes reported | Component estimate only |
| Ipamorelin pulse | Two to three hours reported | Component claim only |
| Interaction | Not established | No fixed-blend PK |
CJC-1295 without DAC + Ipamorelin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous blend | 100 mcg + 100 mcg | Once daily | Clinic-blog claim | No |
| Subcutaneous blend | 100–200 mcg each | Twice daily | Clinic-blog claim | No |
| Subcutaneous blend | 200–300 mcg each | Three times daily | Clinic-blog claim | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
CJC-1295 without DAC + Ipamorelin Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.2 mg | 0.04 mL | 4 units |
| 0.4 mg | 0.08 mL | 8 units |
| 0.6 mg | 0.12 mL | 12 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How CJC-1295 without DAC + Ipamorelin Works
GHRH pathway
Mod GRF(1-29) is intended to stimulate GHRH receptors.
CJC-1295 without DAC + Ipamorelin Human Trials and FDA Status
Current status · verified September 15, 2026
Research-use listing; not FDA approved
- No controlled human trial of the fixed blend was identified.
- No animal pharmacology or interaction study of the fixed blend was identified.
- The supplied clinic article cites no peer-reviewed evidence for its schedule or claimed outcomes.
- Separate-component evidence cannot be combined into a blend evidence level.
- The fixed blend has no approved indication.
Who Should Avoid CJC-1295 without DAC + Ipamorelin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active or recent cancer
GH and IGF-1 pathway concern
Uncontrolled diabetes
Metabolic effects are uncertain
Pituitary or acromegaly disorder
Pathway-specific concern
Pregnancy or breastfeeding
No blend safety data
Concurrent medicines
No interaction studies
Tested athletes
GH secretagogues are prohibited
CJC-1295 without DAC + Ipamorelin Side Effects, Risks and Safety
Water retentionClinic reported
Important limitation: No blend incidence data.
Increased hungerClinic reported
Important limitation: Attributed to ghrelin signaling.
Tingling or numbnessClinic reported
Important limitation: Causality uncertain.
Headache or fatigueClinic reported
Important limitation: No controlled incidence.
Glucose effectsUnknown
Important limitation: No blend study.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
CJC-1295 without DAC + Ipamorelin Timeline and Monitoring
Six to twelve weeks
Source-claimed skin timeline; not trial measured.
Twelve to twenty-four weeks
Source-claimed body-composition timeline; not trial measured.
Rest period
Four to eight weeks reported; no restart criteria are established.
CJC-1295 without DAC + Ipamorelin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Growth-hormone pulse | Not established for blend | Mechanistic claim | No blend study |
| Sleep or recovery | Not established | Clinic-blog claim | No controlled evidence |
| Skin or body composition | Not established | Marketing timeline | No cited trial |
| Synergy | Not established | Two-pathway hypothesis | No interaction study |
CJC-1295 without DAC + Ipamorelin Storage and Handling
Unreconstituted vial
No fixed-blend stability study was identified.
Prepared vial
The source's 28–30 day refrigeration claim is not validated product stability evidence.
Co-formulation
Compatibility and degradation of the mixture are not independently established.
Appearance
Visual inspection cannot establish identity, purity, or sterility.
CJC-1295 without DAC + Ipamorelin Troubleshooting
The total mg is confusing
Confirm whether an amount means total blend or each component.
A DAC schedule appears
This blend uses the no-DAC form; schedules are not interchangeable.
Same-syringe compatibility is claimed
Treat it as an uncited clinic-blog statement.
Product testing is pending
Do not describe the current batch as verified.
A scheduled amount is missed
No validated missed-dose procedure exists.
CJC-1295 without DAC + Ipamorelin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| CJC no DAC + Ipamorelin | Two-pathway fixed blend | No direct studies | Not approved |
| CJC without DAC | Short-acting GHRH analogue | No direct protocol-scale trial | Not approved |
| Ipamorelin | Ghrelin-receptor agonist | Component research only | Not approved |
| CJC with DAC | Long-acting GHRH analogue | Early human PK/PD | Not this blend |
CJC-1295 without DAC + Ipamorelin Frequently Asked Questions
What is in this blend?
CJC-1295 without DAC and Ipamorelin in a vendor-defined mixture.
Has the blend been studied in humans?
No controlled blend trial was identified.
Is it FDA approved?
No.
What is the blend half-life?
Not established.
Is the 1:1 ratio validated?
No.
Can component evidence prove synergy?
No.
Is same-syringe compatibility proven?
The supplied blog claims it, but cites no compatibility study.
Are the result timelines established?
No; they are clinic-marketing claims.
Is a rest period established?
No.
What does the calculator do?
It calculates total-blend concentration and volume only.
Sources and Research
Coverage source
1. CJC-1295 and Ipamorelin dosage guide
Clinic-blog source for schedules and claims; no peer-reviewed blend citations provided.
Open direct sourceRelated-compound research
2. CJC-1295 human pharmacology
DAC-bearing component context only; does not test this blend.
Open direct sourceComponent human research
3. Ipamorelin pharmacology in healthy volunteers
Component-only pharmacology; does not establish fixed-blend use.
Open direct sourceMissing information flagged for review
- Direct blend study: Not established
- Blend pharmacokinetics: Not established
- Validated ratio, dose, and frequency: Not established
- Validated cycle and rest period: Not established
- Co-formulation compatibility: Not established
- Product-specific stability: Not established
- Long-term safety and interactions: Not established